You are here: Industry Insights > Market News > Zydus Cadila receives final approval from USFDA for Albuterol Tablets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Zydus Cadila receives final approval from USFDA for Albuterol Tablets

expresspharmaOctober 26, 2020

Tag: Zydus Cadila , Albuterol Tablets , bronchospasm

Favorites

Zydus Cadila has received final approval from the USFDA to market Albuterol Tablets (US RLD: Proventil Tablets) in the strengths of 2 mg and 4 mg. Albuterol is a bronchodilator. It helps open up the airways in your lungs to make it easier to breathe.

This medicine is used to treat and to prevent bronchospasm. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 310 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Previous:COVAXIN from Bharat Biotech gets DCGI nod for Phase III clinical trials

Next:USFDA approves IND application from Reven Pharma for Rejuveinix to treat COVID-19

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Zydus Cadila receives final approval from USFDA for Albuterol Tablets | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Zydus Cadila receives final approval from USFDA for Albuterol Tablets

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Zydus Cadila receives final approval from USFDA for Albuterol Tablets

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>